![Per-Ola Forsberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Per-Ola Forsberg
Directeur Financier/CFO chez
PHARMIVA AB (PUBL)
Profil
Per-Ola Forsberg is currently the Chief Financial Officer at Pharmiva AB. Previously, he held positions such as Chairman at WC Likvid AB, Director at Probi AB, Chief Financial Officer at Lund University Bioscience AB, Head-Administration at Rechon Life Science AB and PolyPeptide Laboratories (Sweden) AB, Chief Financial Officer at LIDDS AB, Controller at Ball Beverage Packaging Fosie AB, and Chief Financial Officer at Idogen AB. He also served as the Chief Financial Officer at Wntresearch AB from 2016 to 2020.
Mr. Forsberg obtained his undergraduate degree from the University of Lund.
Postes actifs de Per-Ola Forsberg
| Sociétés | Poste | Début |
|---|---|---|
| PHARMIVA AB (PUBL) | Directeur Financier/CFO | 01/02/2020 |
Anciens postes connus de Per-Ola Forsberg
| Sociétés | Poste | Fin |
|---|---|---|
| WNTRESEARCH AB | Directeur Financier/CFO | 11/09/2020 |
Idogen AB
 Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Directeur Financier/CFO | 30/04/2016 |
Lund University Bioscience AB
 Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions. | Directeur Financier/CFO | 30/06/2012 |
Rechon Life Science AB
 Rechon Life Science AB Pharmaceuticals: MajorHealth Technology Produces and markets pharmaceuticals | Directeur Administratif | - |
PolyPeptide Laboratories (Sweden) AB
 PolyPeptide Laboratories (Sweden) AB BiotechnologyHealth Technology Manufactures polypeptide, custom peptide synthesis, peptide synthesis and generic peptides | Directeur Administratif | - |
Formation de Per-Ola Forsberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
25
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Probi AB
 Probi AB BiotechnologyHealth Technology Develops patents probiotic strains for use in nutritional products | Health Technology |
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lund University Bioscience AB
Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions. | Finance |
Wntresearch AB
 Wntresearch AB Pharmaceuticals: OtherHealth Technology Develops novel anti-metastatic therapies based synthetic peptides | Health Technology |
WC Likvid AB
 WC Likvid AB Real Estate DevelopmentFinance Owns and manages movable and immovable property | Finance |
Rechon Life Science AB
Rechon Life Science AB Pharmaceuticals: MajorHealth Technology Produces and markets pharmaceuticals | Health Technology |
PolyPeptide Laboratories (Sweden) AB
PolyPeptide Laboratories (Sweden) AB BiotechnologyHealth Technology Manufactures polypeptide, custom peptide synthesis, peptide synthesis and generic peptides | Health Technology |
LIDDS AB
 LIDDS AB Pharmaceuticals: MajorHealth Technology Focuses on the development of treatment alternatives and hormonal therapy for prostate cancer | Health Technology |
Ball Beverage Packaging Fosie AB
 Ball Beverage Packaging Fosie AB Miscellaneous ManufacturingProducer Manufacturing Manufactures consumer packaging products and solutions | Producer Manufacturing |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Health Technology |
Pharmiva AB
 Pharmiva AB Miscellaneous Commercial ServicesCommercial Services Provides scientific research and development services | Commercial Services |
